Immunoprotein Diagnostic Testing Market size is expected to reach USD 234 billion by the end of 2036, growing at a CAGR of 7% during the forecast period i.e., 2024-2036. In the year 2023, the industry size of immunoprotein diagnostic testing was over USD 73 billion. The growth of this market can be attributed to the growing presence of infectious and chronic diseases. Products for immunoprotein diagnostic testing have increased in popularity due to the high frequency of chronic diseases like infectious diseases, cardiovascular diseases, cancer, obesity, and rheumatoid arthritis. Rapid diagnosis is urgently required due to the chronic diseases' rising mortality rates. Nearly half of all fatalities globally are thought to be caused by infectious diseases like AIDS, malaria, and tuberculosis, according to the Centers for Disease Control and Prevention (CDC).
Chemiluminescence assays have been developed as a result of technological developments in immunoprotein diagnostics. This technique uses fully automated devices and high throughput to assist in the quick detection of chronic diseases. Chemiluminescence tests only require a brief processing period, often between 30 and 45 minutes. This technology allows for on-board reagent capacity to speed up turnaround time and reduces any system workflow interruptions. Additionally, the launch of a wide range of goods has been facilitated by the fusion of complementing laboratory technologies with technological advancements related to immunological reagents and kits.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024 – 2036 |
|
CAGR |
~7% |
|
Base Year Market Size |
~USD 73 billion |
|
Forecast Year Market Size |
~USD 234 billion |
|
Regional Scope |
|
Technology (Chemiluminescence Assay, Enzyme-based Immunoassay, Immunofluorescence Assay, Immunoturbidity Assay, Immunoprotein Electrophoresis)
Immunoprotein diagnostic testing market from the chemiluminescence essay segment is set to hold the largest revenue share of 30% by the end of 2036. The growth may be attributable to a high degree of specificity and sensitivity as well as the ability to identify antigens in human serum or plasma samples. The Chemiluminescence assay is often regarded as an important tool for the rapid identification of a particular disease and it has been shown to be more precise than fluorescently detecting probes, which are labeled. Furthermore, the enzyme-based immunoassay is estimated to offer lucrative growth opportunities for the market in the upcoming time period. In a large number of companies and laboratories, it can also be used to diagnose disease, as well as for quality control. In addition, a large number of EIA analyzers are at the disposal of most major companies. For example, this technology is used for diagnostic purposes in the Human Complement C3 ELISA Kit by Abcam.
Application (Infectious Disease, Endocrine, Toxicology)
The endocrine segment in the immunoprotein diagnostic testing market is estimated to hold a substantial revenue share during the forecast period. The growing burden of endocrine diseases, such as diabetes, and the development of products related to immunodiagnostic testing are driving the growth of this segment. According to 2022 statistics, in the United States, type 1 diabetes increased by 2.9% per year, compared to 4.5% for type 2 diabetes. Similarly, according to the US CDC, in 2022, 96 million adults have prediabetes in the U.S., and 8 out of 10 of them don't know if they have the condition. More than 37 million people are living with diabetes and one in five are undiagnosed. Therefore, the significant increase in the prevalence of diabetes is increasing the demand for immunoprotein testing diagnostics, which will have a positive impact on the market.
Our in-depth analysis of the global market includes the following segments:
|
Product Type |
|
|
Technology |
|
|
Application |
|
APAC Market Forecasts
The immunoprotein diagnostic testing market in the Asia Pacific is estimated to hold the highest share of 35% during the forecast period. This can be assumed due to the extremely rapid economic development coupled with the rapid development of medical health systems in countries such as China and India. Collaboration between public health organizations in China, such as the Ministry of Health, China CDC, and the US CDC, focuses on China's healthcare structure related to HIV/AIDS, vaccination, emerging infectious diseases, non-communicable diseases, and laboratory quality control, have also driven the growth of the market in this area.
North America Market Statistics
The North America immunoprotein diagnostic testing market is expected to grow substantially during the forecast timeframe. Key factors driving market growth in North America include increased healthcare spending and increased awareness of products related to autoimmune disease diagnostics. North America is expected to emerge as a dominant region due to the growing disease burden as well as the development and launch of new products. Furthermore, new product approvals and launches in the region along with collaborations among key market players will drive market growth. For example, in May 2022, OmegaQuant launched an HbA1c test with a sample collection kit for at-home testing. This simple, safe, and practical test measures the amount of sugar (glucose) in the blood. Therefore, it will positively influence the market and witness significant growth in North America during the forecast period due to the above-mentioned factors.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?